Global Information
회사소개 | 문의

세계의 당뇨병 치료제 시장 예측

Global Diabetes Drugs Market Forecast 2019-2027

리서치사 Inkwood Research
발행일 2018년 10월 상품 코드 618296
페이지 정보 영문 132 Pages
가격
US $ 2,500 ₩ 2,846,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 되지 않으며, 인쇄 또한 불가능합니다.
US $ 3,000 ₩ 3,415,000 PDF (Multi User License) help
동일 사업장(소재지) 내 5명까지 이용가능한 라이센스입니다. PDF 파일은 Copy & Paste가 되지 않습니다. 인쇄는 1명당 1회에 한해 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,500 ₩ 5,122,000 PDF (Enterprisewide License) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 당뇨병 치료제 시장 예측 Global Diabetes Drugs Market Forecast 2019-2027
발행일 : 2018년 10월 페이지 정보 : 영문 132 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

세계의 당뇨병 치료제(Diabetes Drugs) 시장에 대해 분석했으며, 제품 개요와 기본적인 시장 구조, 주요 시장 성장 촉진·억제요인, 전체적인 시장 동향 전망(향후 9년간), 질환 종류별·제품 클래스별·지역별 동향, 시장 경쟁 상황, 주요 기업 개요 등의 정보를 전해드립니다.

제1장 분석 범위

제2장 분석 방법

제3장 주요 요약

제4장 시장 역학

  • 용어 설명 : 당뇨병 치료제 시장
  • 시장 정의와 범위
  • 법률상, 정책상, 규제상 과제
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 과제

제5장 당뇨병 종류별 시장

  • 1형 당뇨병
  • 2형 당뇨병

제6장 제품 클래스별 시장

  • 인슐린
    • 속효형 인슐린
    • 중간형 인슐린
    • 지속형 인슐린
  • 비인슐린
    • DPP-4 억제제
    • GLP-1 수용체 작용제
    • SGLT-2 억제제
    • 기타

제7장 주요 분석 지표

  • Porter's Five Forces 분석
    • 신규 진출 기업의 위협
    • 대체 제품의 위협
    • 바이어의 협상력
    • 공급업체의 협상력
    • 기업간 경쟁도
  • 시장 기회 매트릭스
  • 벤더 상황
  • 파이프라인 분석
  • 주요 구입 기준
    • 안전성과 효능
    • 입수 가능성
    • 장기적인 질환 완화 효과
    • 비용 부담력과 비용 효율성
    • 처방약의 의료비 상환

제8장 지역별 분석

  • 북미(미국, 캐나다)
  • 유럽(독일, 영국, 프랑스, 이탈리아 등)
  • 아시아태평양(중국, 인도, 일본, 한국 등)
  • 기타 지역(RoW : 라틴아메리카, 중동 및 아프리카)

제9장 기업 개요

  • ELI LILLY AND COMPANY
    • 개요
    • SCOT 분석
    • 제품 포트폴리오
    • 전략 전개 상황
  • B.BRAUN MELSUNGEN AG
  • NOVO NORDISK A/S
  • SANOFI
  • DIAVACS INC
  • XOMA CORP
  • ALBIREO PHARMA INC
  • MACROGENICS INC
  • ASTELLAS PHARMA
  • GLAXOSMITHKLINE
  • MERCK
  • PFIZER
  • XERIS PHARMACEUTICALS
KSM 18.04.04

KEY FINDINGS

The growth in the global diabetes drugs market is mainly driven by increased diabetic population and obesity rates in recent years. The North American market holds the largest share of the global market. The global diabetes drugs market is expected to grow at a CAGR of 6.50% during the forecast period of 2019-2027.

MARKET INSIGHTS

The important driver for the growth in this market is the increase in the prevalence of diabetes which is because of the increasing obesity among people caused by unhealthy diets and sedentary lifestyles. The diabetes drugs market segments include diabetes type and product class. Diabetes drugs manufacturers offer products for use by both the types (type 1 and type 2) of diabetic patients. Growing elderly population is also influencing the market growth in a big way as the life expectancy rate is rising and the birth rate is declining at the same time.

REGIONAL INSIGHTS

The major countries considered in every region are North America (The United States and Canada), Europe (Germany, United Kingdom, France, Italy, and Rest of Europe) and Asia-Pacific (China, India, Japan, South Korea and Rest of Asia Pacific). Rising prevalence of diabetes and obesity rate is anticipated to be the key factors for the growth of the diabetes market. Global vendors are expanding their business by establishing their manufacturing facilities in developing countries. Vendors are focusing on strategic collaborations with domestic distribution partners and suppliers to improve their distribution channels.

COMPETITIVE INSIGHTS

Leading brands in the global market of diabetes drugs are Eli Lilly And Company, AstraZeneca Plc., B.Braun Melsungen Ag, Novo Nordisk A/S, Sanofi, Diavacs Inc., Xoma Corp., Albireo Pharma Inc., Macrogenics Inc., Astellas Pharma, Glaxosmithkline, Merck, Pfizer and Xeris Pharmaceuticals.

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. RISING PREVALENCE OF TYPE 2 DIABETES
    • 3.2.2. INSULIN MARKET IS ANTICIPATED TO GENERATE THE HIGHEST REVENUE

4. MARKET DETERMINANTS

  • 4.1. MARKET DRIVERS
    • 4.1.1. INCREASE IN PREVALENCE OF DIABETES
    • 4.1.2. ADVANCES IN INSULIN TECHNOLOGY
    • 4.1.3. GROWING ELDERLY POPULATION
  • 4.2. MARKET RESTRAINTS
    • 4.2.1. LACK OF AWARENESS AMONG PEOPLE
    • 4.2.2. COST SENSITIVITY ISSUES
  • 4.3. MARKET OPPORTUNITIES
    • 4.3.1. DEVELOPMENT OF NEW FORMULATIONS
    • 4.3.2. INCREASING RESEARCH AND DEVELOPMENT
  • 4.4. MARKET CHALLENGES
    • 4.4.1. FIERCE MARKET COMPETITION
    • 4.4.2. RISING CONCERNS IN SCIENTIFIC COMMUNITY
    • 4.4.3. GAPS IN NATIONAL-LEVEL DIABETES MANAGEMENT PLANS
    • 4.4.4. POOR STORAGE CONDITIONS AND DISTRIBUTION POLICIES FOR INSULIN

5. MARKET SEGMENTATION

  • 5.1. MARKET BY DIABETES TYPE 2019-2027
    • 5.1.1. TYPE 1
    • 5.1.2. TYPE 2
  • 5.2. MARKET BY PRODUCT CLASS 2019-2027
    • 5.2.1. INSULIN
      • 5.2.1.1. FAST ACTING INSULIN
      • 5.2.1.2. INTERMEDIATE ACTING INSULIN
      • 5.2.1.3. LONG-ACTING INSULIN
    • 5.2.2. NON-INSULIN
      • 5.2.2.1. DPP-4 INHIBITOR
      • 5.2.2.2. GLP-1 RECEPTORS AGONISTS
      • 5.2.2.3. SGLT-2 INHIBITORS
      • 5.2.2.4. OTHER NON-INSULIN DRUGS

6. KEY ANALYTICS

  • 6.1. PORTERS FIVE FORCES ANALYSIS
    • 6.1.1. THREAT OF NEW ENTRANTS
    • 6.1.2. THREAT OF SUBSTITUTE
    • 6.1.3. BARGAINING POWER OF SUPPLIERS
    • 6.1.4. BARGAINING POWER OF BUYERS
    • 6.1.5. THREAT OF COMPETITIVE RIVALRY
  • 6.2. OPPORTUNITY MATRIX
  • 6.3. ETYMOLOGY OF DIABETES DRUGS MARKET
  • 6.4. LEGAL, POLICY AND REGULATORY ISSUES

7. GEOGRAPHICAL ANALYSIS

  • 7.1. ASIA-PACIFIC (APAC)
    • 7.1.1. CHINA
    • 7.1.2. INDIA
    • 7.1.3. AUSTRALIA
    • 7.1.4. JAPAN
    • 7.1.5. SOUTH KOREA
    • 7.1.6. INDONESIA
    • 7.1.7. MALAYSIA
    • 7.1.8. PHILIPPINES
    • 7.1.9. THAILAND
    • 7.1.10. VIET NAM
    • 7.1.11. REST OF ASIA-PACIFIC (ROAPAC)

8. COMPANY PROFILES

  • 8.1. ELI LILLY AND COMPANY
    • 8.1.1. OVERVIEW
    • 8.1.2. PRODUCTS PORTFOLIO
    • 8.1.3. SWOT ANALYSIS
    • 8.1.4. STRATEGIC INITIATIVES
  • 8.2. ASTRAZENECA PLC.
    • 8.2.1. OVERVIEW
    • 8.2.2. PRODUCT PORTFOLIO
    • 8.2.3. SWOT ANALYSIS
    • 8.2.4. STRATEGIC INITIATIVES
  • 8.3. B.BRAUN MELSUNGEN AG
    • 8.3.1. OVERVIEW
    • 8.3.2. PRODUCT PORTFOLIO
    • 8.3.3. SCOT ANALYSIS
    • 8.3.4. STRATEGIC ANALYSIS
  • 8.4. NOVO NORDISK A/S
    • 8.4.1. OVERVIEW
    • 8.4.2. PRODUCTS PORTFOLIO
    • 8.4.3. SWOT ANALYSIS
    • 8.4.4. STRATEGIC INITIATIVES
  • 8.5. SANOFI
    • 8.5.1. OVERVIEW
    • 8.5.2. PRODUCTS PORTFOLIO
    • 8.5.3. SWOT ANALYSIS
    • 8.5.4. STRATEGIC INITIATIVES
  • 8.6. DIAVACS INC.
    • 8.6.1. OVERVIEW
    • 8.6.2. PRODUCT PORTFOLIO
    • 8.6.3. SWOT ANALYSIS
  • 8.7. XOMA CORP.
    • 8.7.1. OVERVIEW
    • 8.7.2. PRODUCT PORTFOLIO
    • 8.7.3. SWOT ANALYSIS
    • 8.7.4. STRATEGIC INITIATIVES
  • 8.8. ALBIREO PHARMA INC.
    • 8.8.1. OVERVIEW
    • 8.8.2. PRODUCT PORTFOLIO
    • 8.8.3. SWOT ANALYSIS
  • 8.9. MACROGENICS, INC.
    • 8.9.1. OVERVIEW
    • 8.9.2. PRODUCT PORTFOLIO
    • 8.9.3. SWOT ANALYSIS
  • 8.10. ASTELLAS PHARMA
    • 8.10.1. OVERVIEW
    • 8.10.2. PRODUCT PORTFOLIO
    • 8.10.3. SWOT ANALYSIS
    • 8.10.4. STRATEGIC INITIATIVES
  • 8.11. GLAXOSMITHKLINE
    • 8.11.1. OVERVIEW
    • 8.11.2. PRODUCT PORTFOLIO
    • 8.11.3. SWOT ANALYSIS
  • 8.12. MERCK
    • 8.12.1. OVERVIEW
    • 8.12.2. PRODUCT PORTFOLIO
    • 8.12.3. SWOT ANALYSIS
    • 8.12.4. STRATEGIC INITIATIVES
  • 8.13. PFIZER
    • 8.13.1. OVERVIEW
    • 8.13.2. PRODUCT PORTFOLIO
    • 8.13.3. SWOT ANALYSIS
    • 8.13.4. STRATEGIC INITIATIVES
  • 8.14. XERIS PHARMACEUTICALS
    • 8.14.1. OVERVIEW
    • 8.14.2. PRODUCT PORTFOLIO
    • 8.14.3. SWOT ANALYSIS
    • 8.14.4. STRATEGIC INITIATIVES

TABLE LIST

  • TABLE 1 ASIA PACIFIC DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
  • TABLE 2 ASIA PACIFIC DIABETES DRUGS MARKET BY DIABETES TYPES 2019-2027, ($ MILLION)
  • TABLE 3 ASIA PACIFIC DIABETES DRUGS MARKET IN TYPE 1 DIABETES 2019-2027 ($ MILLION)
  • TABLE 4 ASIA PACIFIC DIABETES DRUGS MARKET IN TYPE 2 DIABETES 2019-2027 ($ MILLIONS)
  • TABLE 5 ASIA PACIFIC DIABETES DRUGS MARKET BY PRODUCT CLASS 2019-2027 ($ MILLIONS)
  • TABLE 6 ASIA PACIFIC DIABETES DRUGS MARKET IN INSULIN TYPE 2019-2027 ($ MILLION)
  • TABLE 7 ASIA PACIFIC DIABETES DRUGS MARKET IN INSULIN BY TYPES 2019-2027 ($ MILLION)
  • TABLE 8 ASIA PACIFIC INSULIN MARKET IN FAST ACTING INSULIN 2019-2027 ($ MILLION)
  • TABLE 9 ASIA PACIFIC INSULIN MARKET IN INTERMEDIATE ACTING INSULIN 2019-2027 ($ MILLION)
  • TABLE 10 ASIA PACIFIC INSULIN MARKET IN LONG ACTING INSULIN 2019-2027 ($ MILLION)
  • TABLE 11 ASIA PACIFIC DIABETES DRUGS MARKET IN NON-INSULIN DRUGS 2019-2027 ($ MILLION)
  • TABLE 12 ASIA PACIFIC DIABETES DRUGS MARKET IN NON-INSULIN DRUGS BY TYPES 2019-2027 ($ MILLION)
  • TABLE 13 ASIA PACIFIC NON-INSULIN DRUGS MARKET IN DPP-4 INHIBITOR 2019-2027 ($ MILLION)
  • TABLE 14 ASIA PACIFIC NON-INSULIN DRUGS MARKET IN GLP-1 RECEPTORS AGONISTS 2019-2027 ($ MILLION)
  • TABLE 15 ASIA PACIFIC NON-INSULIN DRUGS MARKET IN SGLT-2 INHIBITORS 2019-2027 ($ MILLION)
  • TABLE 16 ASIA PACIFIC NON-INSULIN DRUGS MARKET IN OTHER NON-INSULIN DRUGS 2019-2027 ($ MILLION)
  • TABLE 17 ASIA-PACIFIC DIABETES DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

FIGURES LIST

  • FIGURE 1 ASIA PACIFIC DIABETES DRUGS MARKET 2019-2027 ($ BILLION)
  • FIGURE 2 ASIA PACIFIC DIABETES DRUGS MARKET, BY TYPE 2 DIABETES 2019-2027 ($ MILLION)
  • FIGURE 3 AVERAGE LIFE EXPECTANCY AT BIRTH IN 2017, BY GENDER (IN YEARS)
  • FIGURE 4 PORTER'S FIVE FORCES ANALYSIS OF DIABETES DRUGS MARKET
  • FIGURE 5 CHINA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 6 INDIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 7 AUSTRALIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 8 JAPAN DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 9 SOUTH KOREA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 10 INDONESIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 11 MALAYSIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 12 PHILIPPINES DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 13 THAILAND DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 14 VIETNAM DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 15 REST OF ASIA-PACIFIC DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
Back to Top
전화 문의
이용안내
 
BCC Research